American National Bank & Trust Cuts Holdings in Pfizer Inc. (NYSE:PFE)

American National Bank & Trust cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 72.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,853 shares of the biopharmaceutical company's stock after selling 81,866 shares during the quarter. American National Bank & Trust's holdings in Pfizer were worth $782,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mcdonald Partners LLC lifted its holdings in shares of Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after buying an additional 9,963 shares during the period. Bank of Jackson Hole Trust bought a new position in shares of Pfizer during the 4th quarter valued at $264,000. Harvey Capital Management Inc. bought a new position in shares of Pfizer during the 4th quarter valued at $544,000. ING Groep NV lifted its holdings in shares of Pfizer by 48.6% during the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock valued at $26,881,000 after buying an additional 331,403 shares during the period. Finally, WCM Investment Management LLC lifted its holdings in shares of Pfizer by 128.7% during the 4th quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company's stock valued at $3,062,000 after buying an additional 65,238 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Finally, UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

PFE stock traded down $0.09 during trading on Tuesday, reaching $23.37. The company's stock had a trading volume of 35,431,800 shares, compared to its average volume of 41,025,205. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $132.85 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company's fifty day moving average is $23.08 and its 200-day moving average is $25.04.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.